| Malaria is one of the three most serious infectious diseases in the world.About half of the world’s population is at risk of malaria.In China,there are still cases of malaria infection in some areas.Malaria is caused by the Anopheles mosquito carrying the infectious source when it bites the human body.The malaria parasite eggs carried into the human body have a certain incubation period.The malaria parasite gametophyte develops into a sporozoite in the stomach of the re-sucking mosquito,causing further infection.Microscopic examination and PCR nucleic acid amplification test are clinically available malaria detection methods,which have the problems of low efficiency,high cost,cumbersome use,and difficult storage and transportation of products.Therefore,it is of great clinical value to develop a rapid,simple,low-cost and stable malaria diagnosis product.In this study,phage display technology was used to select n ABPs from the display framework protein library constructed by professor Darren from the university of Leeds in the United Kingdom by using plasmodium falciparum histidine-rich protein-2(HRP2)and plasmodium vivax lactate dehydrogenase(LDH)as target antigens.Using genetic engineering technology for recombinant expression and purification to obtain n ABPs,establish a colloidal gold immunochromatographic assay,verify and compare its performance at the laboratory and clinical level,and develop a low-cost,high-performance rapid detection and diagnosis kit for malaria.According to the statistical analysis of preliminary clinical trials,the positive coincidence rate was 97.9%%,the negative coincidence rate was 95.5%,the total coincidence rate was 96.9%,the Yoden index reached 0.934,Kappa = 0.936,and the storage stability at room temperature was more than 3 years.The malaria colloidal gold detection reagent developed by n ABPs prepared by phage display technology has high detection performance,simple use,easy storage and high clinical application value. |
PDF Full Text Request